APOE and Alzheimer disease: In a clinical trial, patients with mild-to-moderate AD were randomized to placebo or rosiglitazone treatment and the exploratory analyses suggested an improvement in cognitive and functional measures in ApoE ε4 non-carriers, whereas no improvement and some decline was noted in the ApoE ε4 allele carriers [130].